GALT Galectin Therapeutics Inc.: Stock Price

The daily price chart for Galectin Therapeutics (GALT) illustrates the quotes of the company developing innovative liver therapies, where the key metric stands at 3.05. The business leverages the acute shortage of therapies for cirrhosis and NASH, ensuring high physician interest. Success is driven by management's transparency regarding clinical trials and a team of dedicated scientists striving for medical breakthroughs.

Price Chart: Galectin Therapeutics Inc. (GALT) for 07/04/2022 - 11/14/2026

Galectin - analytical breakdowns and key metrics (GALT)

- stock quotes and analyst forecast:

Stock Price Galectin Therapeutics|GALT - Analyst Target Range

- company stock capitalization data:

Market Capitalization Galectin Therapeutics, Inc.|GALT - Enterprise Value

- book capitalization information:

Net Assets per Single Share Galectin Therapeutics|GALT - Company Book Value|Market Cap to Net Assets Ratio galectintherapeutics.com|GALT - Aggregate Business Assets

- company liabilities and liquidity data:

- company profitability and valuation multiples indicators:

GALT - Net Income|Projected Future Earnings Galectin Therapeutics|GALT - P/E Multiple|Projected Price to Earnings Galectin Therapeutics|GALT - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galectin Therapeutics, Inc.|GALT - Profit before payment of interest, taxes and amortization|Net earnings per share (EPS TTM) Galectin Therapeutics|GALT - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months galectintherapeutics.com|GALT - Earnings per share growth in current year|Earnings growth forecast for next year Galectin Therapeutics

- issuer revenue and sales details:

GALT - Company Total Revenue|Company Projected Revenue Galectin Therapeutics|GALT - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Galectin Therapeutics, Inc.

Fundamental valuation:Galectin Therapeutics Inc.

The assessment of the asset's operational resilience is based on an analysis of the market value of rights to future earnings, where the market value chart allows for the separation of short-term noise from the long-term capitalization trend. For Galectin Therapeutics (GALT), this indicator reflects the speculative anticipation of belapectin trial results, turning the price into a barometer of binary risk between commercial success and the threat of a liquidity shortage.

Analysis of competing companies